M

    MIRA Pharmaceuticals, Inc. Common Stock (MIRA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $0.77
    +0.02 (+2.68%)

    Market Cap: $31.52M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(5/10)
    Avg Surprise
    -34.75%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.03N/AN/ABeat+66.7%
    Mar 26
    		$-0.03N/AN/ABeat+75.1%
    Dec 25
    		$-0.14$-0.08-78.38%Miss+18.5%
    Sep 25
    		$-0.07$-0.08+12.50%Beat+50.0%
    Jun 25
    		$-0.09$-0.13+30.77%Beat+18.2%
    Mar 25
    		$-0.11$-0.14+21.43%Beat+8.3%
    Dec 24
    		$-0.17$-0.13-34.62%Miss+52.7%
    Sep 24
    		$-0.14$-0.15+6.67%Beat+46.2%
    Jun 24
    		$-0.11$-0.11+0.00%Beat-10.0%
    Mar 24
    		$-0.12$-0.10-20.00%Miss-
    Dec 23
    		$-0.37$-0.23-60.87%Miss-
    Sep 23
    		$-0.26$-0.08-225.00%Miss-
    Jun 23
    		$-0.10$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.85EV/EBITDA-1.45x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-217.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-150.05x
    Current Ratio200.08xQuick Ratio200.08x
    Trading Statistics
    Beta1.55Avg Volume92.46K
    52-Week High$2.4552-Week Low$0.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.76
    SMA 20$0.75
    SMA 50$0.84
    SMA 200$1.12
    EMA 10$0.76
    EMA 20$0.77
    EMA 50$0.83
    EMA 200$1.04

    MACD

    Line: -0.02Signal: -0.03Hist: 0.01

    ADX

    ADX: 18.4+DI: 12.8-DI: 19.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down20.0
    PSAR$0.73

    Bollinger Bands

    Upper Band$0.83
    Lower Band$0.67
    %B Position2064%(Upper)
    Band Width0.64

    RSI (14-Day)

    Neutral
    47.9

    Momentum Oscillators

    Stoch %K46.4
    Stoch %D50.2
    Williams %R-47.7
    ROC (10d)-2.5%
    Momentum-0.02
    CCI (20d)30.0
    MFI (14d)72.7

    Volatility Measures

    ATR (14d)$0.06(7.3%)
    StdDev (20d)0.04
    Hist Vol73.0%(High)

    Volume Flow

    VWAP$0.77
    OBV212.7M
    AD Line-99.1M
    CMF (20d)-0.230

    Volume Metrics

    Avg Vol (20d)75.9K
    Vol Ratio0.6x
    VWMA (20d)$0.73

    Pivot Points

    R3$0.80
    R2$0.79
    R1$0.77
    Pivot Point$0.76
    S1$0.74
    S2$0.73
    S3$0.71

    Advanced Oscillators

    TSI-10.03
    Ultimate Osc35.6
    KST-87.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$1.16M$1.10M$5.82M$1.32M$1.55M$1.81M$2.44M$2.08M$1.73M$1.77M$3.06M$3.16M
    R&D$705,789$524,781$496,543$412,639$496,197$314,404$861,441$1.07M$614,462$762,276$387,123$1.02M
    SG&A$450,330$578,698$5.33M$904,346$1.05M$1.49M$1.58M$1.01M$1.12M$1.01M$2.67M$2.14M
    Operating Income$-1,156,119$-1,103,479$-5,824,827$-1,316,985$-1,546,100$-1,805,200$-2,437,800$-2,081,619$-1,730,722$-1,768,187$-3,056,354$-3,160,084
    Interest Income$0$0$0$0$0$0$0$0$39,397$0$0$0
    Interest Expense$-35,130$-44,909$158,494$-15,697$-8,623$-21,421$0$-37,752$0$-50,416$2.73M$427,732
    Income Before Tax$-1,208,534$-1,150,152$-5,983,321$-1,137,673$-1,537,712$-1,783,779$-2,399,696$-2,043,867$-1,691,325$-1,717,771$-5,787,376$-3,587,816
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,208,534$-1,150,152$-5,983,321$-1,137,673$-1,537,712$-1,783,779$-2,399,696$-2,043,867$-1,691,325$-1,717,771$-5,787,376$-3,587,816
    EBITDA$-1,243,664$-1,195,061$-5,824,827$-1,153,370$-1,546,335$-1,805,200$-2,437,800$-2,081,619$-1,730,722$-1,768,187$-3,056,354$-2,720,709
    EBIT$-1,243,664$-1,195,061$-5,824,827$-1,153,370$-1,546,335$-1,805,200$-2,437,800$-2,081,619$-1,730,722$-1,768,187$-3,056,354$-3,160,084
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MIRA

    News

    MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

    MIRA Pharmaceuticals, Inc. announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs, an obesity treatment candidate designed to preserve lean body mass. The study demonstrated rapid oral absorption and dose-dependent systemic exposure, de-risking dose selection and supporting advancement toward GLP toxicology studies and IND-enabling development. SKNY-1 aims to address the common issue of lean muscle loss with current obesity treatments.

    GlobeNewswire•8/7/26•
    Bullish

    Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com

    This article announces that Mira Pharmaceuticals Inc. filed a Form 8K on August 6. The content is very brief, mainly serving as a notification about the SEC filing. The company's stock symbol is MIRA, and it showed a 9.11% increase.

    Investing.com South Africa•8/6/26•
    Neutral

    MIRA's obesity candidate shows rapid absorption in 7-day dog study

    MIRA Pharmaceuticals reported positive toxicokinetic results from a 7-day repeated-dose study of its obesity candidate, SKNY-1, in Beagle dogs. The study showed rapid absorption, dose-dependent systemic exposure, and systemic accumulation, which de-risks dose selection for planned GLP toxicology studies. These findings support the advancement of SKNY-1 towards IND-enabling development, with previous preclinical work indicating dose-dependent weight loss while preserving lean body mass and no anxiety-related effects.

    Stock Titan•8/6/26•
    Bullish

    MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

    MIRA Pharmaceuticals, Inc. announced positive toxicokinetic findings from a 7-day repeated-dose study of its obesity treatment candidate, SKNY-1, in Beagle dogs. The study showed rapid absorption and dose-dependent systemic exposure, which de-risks dose selection and supports further development towards IND-enabling studies. SKNY-1 aims to address obesity without lean muscle loss, a common issue with current treatments.

    Yahoo Finance Singapore•8/6/26•
    Bullish

    Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Mira Pharmaceuticals Inc (MIRA) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average at 8.10. Analysts provide a consensus price target of $3.00, suggesting a significant upside of +109.79%. There are no analysts providing individual ratings for MIRA as of the latest update.

    TradingKey•8/5/26•
    Somewhat-Bullish

    Frequently Asked Questions About MIRA

    Does MIRA pay dividends?
    MIRA Pharmaceuticals, Inc. Common Stock (MIRA) does not currently pay a regular dividend.
    What is MIRA's market cap?
    MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has a market capitalization of $31.52M with a current stock price of $0.77.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In